Dr. Berenson on the Study of Zometa in Multiple Myeloma

Video

James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.

James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Related Content
OncLive On Air

Revisit Every OncLive On Air Episode from March 2024

April 19th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
David L. Porter, MD

Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain

April 18th 2024
Article
Matthew Lunning, DO, FACP

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

November 30th 2023
Podcast
Paul G. Richardson, MD, of Dana-Farber Cancer Institute

Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma

April 18th 2024
Article
Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

April 17th 2024
Article